TIGIT and cancer: Additionally, in PD-L1-positive NSCLC cancer patients, the combined PD-L1/TIGIT inhibition (atezolizumab + tiragolumab) leads to greater clinical benefits in comparison with PD-L1 inhibition alone, despite having similar toxicity profiles [66].